Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study.

Hum Vaccin Immunother · 2025 · PMC12087486 · PMID 40381203

Europe PMC DOI

hedged sentence

0.1707

closest p · 3.4× alpha

0.1707

boldest claim

The sentences

did not reach statistical significancep = .1707not close (p > 0.1)

Similarly, while seroconversion rates based on a four-fold increase were highest in the RHCH (86.67%) and RLCH (80%) groups and lowest in the Sinovac group (45.45%), this trend did not reach statistical significance ( p = .1707) in Figure 5 and Table S3 (Suppl.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.